Hematology · 1 h ago
Baseline features associated with long-term survival in primary myelofibrosis
A retrospective cohort study examined 217 people diagnosed with primary myelofibrosis before 2001, including 41 who survived more than 25 years. Younger age, platelet count above 450 × 10⁹/L and grade-0 bone marrow fibrosis were independently associated with long-term survival.
- 41 of 217 analyzed patients survived more than 25 years.
- Age under 50 independently predicted long-term survival.
- Platelets above 450 × 10⁹/L and grade-0 fibrosis were associated with survival.
- Retrospective historical cohort; findings are prognostic associations.
Researchers retrospectively analyzed a historical institutional cohort of people diagnosed with primary myelofibrosis (PMF) before January 2001. After excluding patients who received allogeneic stem-cell transplantation, the analysis compared 41 people who survived more than 25 years with 176 who died within 25 years. The investigators assessed baseline clinical, hematologic and molecular characteristics and used logistic regression, with a 10-year landmark Cox analysis to examine overall survival associations.
Long-term survivors were younger at diagnosis than the comparison group (median 36 vs 58 years); 90% were younger than 50. In multivariable analyses, age under 50, platelet count above 450 × 10⁹/L and grade-0 bone marrow fibrosis independently predicted survival beyond 25 years. Long-term survivors also had a lower cumulative incidence of anemia and thrombocytopenia during follow-up. The reported associations were confirmed in the landmark analysis.
These findings describe features associated with exceptionally long survival and may inform prognostic assessment. They do not establish that these features should determine treatment: the study was retrospective, involved a historical cohort diagnosed before 2001, and excluded transplant recipients. The results should therefore be interpreted as prognostic associations rather than evidence of treatment benefit or a validated change to current management.
In practice
In this historical PMF cohort, age under 50 years, platelet count above 450 × 10⁹/L and grade-0 marrow fibrosis at diagnosis were independently associated with survival beyond 25 years. These features may help characterize prognosis, but the study does not show that they predict response to a particular treatment or justify changing therapy. The retrospective cohort was diagnosed before 2001 and excluded allogeneic transplant recipients, so applicability to contemporary patients and management remains uncertain.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Leukemia: Predicting long-term survival in primary myelofibrosis ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.